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Metabolic syndrome predicts worse perioperative outcomes in patients treated 
with partial nephrectomy for renal cell carcinoma 
 
Stefano Luzzago
a,b
, Carlotta Palumbo
a,c
 Giuseppe Rosiello
a,d
, Angela Pecoraro
a,e
, 
Marina Deuker
a,f
, Franziska Stolzenbach
a,g
, Francesco Alessandro Mistretta
a,b
, Zhe 
Tian
a
, Gennaro Musi
b
, Emanuele Montanari
h
, Shahrokh F. Shariat
i,l,m,n,o
, Fred Saad
a
, 
Alberto Briganti
d
, Ottavio de Cobelli
b,p
, Pierre I. Karakiewicz
a
 
 
aCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health 
Center, Montreal, Quebec, Canada 
bDepartment of Urology, European Institute of Oncology, IRCCS, Milan, Italy 
cUrology Unit, ASST Spedali Civili of Brescia. Department of Medical and Surgical Specialties, 
Radiological Science and Public Health, University of Brescia, Italy 
dDepartment of Urology and Division of Experimental Oncology, URI, Urological Research Institute, 
IRCCS San Raffaele Scientific Institute, Milan, Italy 
eDepartment of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy 
fDepartment of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany 
gMartini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
hDepartment of Urology, IRCCS Fondazione Ca’ Granda-Ospedale Maggiore Policlinico, University 
of Milan, Milan, Italy 
iDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 
Austria 
lDepartments of Urology, Weill Cornell Medical College, New York, New York, USA 
mDepartment of Urology, University of Texas Southwestern, Dallas, Texas, USA 
nDepartment of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republicm  
oInstitute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical 
University, Moscow, Russia 
pDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy 
 
Corresponding author: 
Stefano Luzzago, MD 
Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy 
Via Giuseppe Ripamonti, 435 
20141 Milan, Italy 
Tel: +39 33354249298 
E-mail: stefanoluzzago@gmail.com 
 
Word count (abstract): 250 
Word count (manuscript): 2556 
Declarations of interest: None 
         
 Keywords: Altered fasting glucose; High blood pressure; High triglycerides; Metabolic syndrome; 
Obesity; Partial Nephrectomy 
Research support and financial conflicts of interest: None 
Acknowledgements: None 
  
         
Abstract 
Objectives 
To test the association between metabolic syndrome (MetS) and its components (high blood 
pressure, BMI 30, altered fasting glucose, low HDL cholesterol and high triglycerides) on 
perioperative outcomes after partial nephrectomy (PN). 
 
Methods 
Within the NIS database (2000-2015) we identified all PN patients. First, temporal trends of MetS 
were reported. Second, the effect of MetS components was tested in multivariable logistic 
regression models predicting overall and specific perioperative complications. Third, we tested for 
dose-response from the concomitant effect of multiple MetS components. All models were 
weighted and adjusted for clustering, as well as all available patient and hospital characteristics. 
 
Results 
Of 25,875 patients:1)59.3% had high blood pressure, 2)14.7% had BMI 30, 3)21.7% had altered 
fasting glucose, 4)20.2% had high triglycerides and 5)<0.01% had low HDL cholesterol. One vs. 
two vs. three vs. four MetS components were recorded in 34.9% vs. 22.9% vs. 8.9% vs. 2.2% 
patients. Of all, 11.1% exhibited  3 components and qualified for MetS. The rates of MetS 
increased over time (EAPC:+12.0%;p<0.001). The four tested MetS components (high blood 
pressure, BMI 30, altered fasting glucose and high triglycerides) achieved independent predictor 
status in multivariable models predicting overall, cardiac, miscellaneous medical, vascular and 
respiratory complications, as well as transfusions. Moreover, a statistically significant dose-
response was confirmed for the same endpoints. 
 
Conclusion 
         
MetS and its components consistently and strongly predict perioperative complications after PN. 
Moreover, the strength of the effect was directly proportional to the number of MetS components 
exhibited by each individual patient, even if formal MetS diagnosis of  3 components has not been 
met.  
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1. Introduction 
  Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease, which 
occur together more often than by chance alone 
1
. These risk factors include: high blood pressure, 
altered fasting glucose, obesity, high triglycerides and low high-density lipoprotein (HDL) 
cholesterol. It is estimated that approximately 35% of North American population is affected by 
MetS 
2
. Moreover, MetS is associated with aggressive pathological features of renal cell carcinoma 
(RCC) 
3,4
. However, there are no robust data to indicate whether or not MetS predicts early adverse 
outcomes after partial nephrectomy (PN) 
5–9
. Nonetheless, several previous reports examined the 
effect of individual MetS components, namely either obesity 
10–18
 or hypertension 
19–21
 or diabetes 
21–25
, on perioperative outcomes after PN, without adjusting for possible combined effect of other 
MetS components. Moreover, none of previous studies addressed the possible synergistic effect of 
multiple MetS components on perioperative complications after PN. To address these limitations, 
we tested the effect of MetS on overall and specific complications, in PN treated patients.  
  
         
2. Materials and methods 
2.1 Study population 
 We relied on the National Inpatient Sample (NIS) database (2000-2015) 
26
 that is composed 
of longitudinal hospital inpatient databases from the Healthcare Cost and Utilization Project and 
includes 20% of United States inpatient hospitalizations. We focused on patients aged≥18 years 
with primary diagnosis of RCC (International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] code 1890), treated with PN (primary procedure ICD-9-CM code 55.4). 
Secondary procedure codes were used to identify lymph node dissection (ICD-9-CM codes 
40.3/40.5), as well as open, laparoscopic or robotic approach (ICD-9-CM codes 17.4, 54.21 or 
17.42). 
 
2.2 Outcomes of interest 
We focused on overall and specific perioperative complications. Overall complications were 
defined using secondary ICD-9-CM diagnostic codes and represented the sum of intraoperative and 
all postoperative complications (cardiac, respiratory, vascular, wound, genitourinary, 
gastrointestinal, infectious, transfusions, miscellaneous medical and miscellaneous surgical). 
Specifically, the outcome transfusion refers to the need of patients to receive blood products. 
 
2.3 Variables definition 
MetS was defined according to the International Diabetes Federation and the American 
Heart Association/National Heart, Lung, and Blood Institute 
1
. Specifically, MetS definition was 
based on having at least three out of five MetS components, namely: 1) high blood pressure, 2) 
BMI 30, 3) altered fasting glucose, 4) high triglycerides and 5) low HDL cholesterol 
(Supplementary table 1) 
27,28
. Covariables consisted of: age, gender, ethnicity (Caucasian, African-
American and Others), year of surgery, surgical approach (open vs. laparoscopic/robotic), lymph 
node dissection, income and insurance status (private, Medicare, Medicaid, other), hospital region 
         
(Northeast, Midwest, South, West), hospital teaching vs. non-teaching status, hospital bed size 
(small, medium, large) and hospital annual volume (low, medium, high), which represents the 
number of PNs performed at each participating institution during each study calendar year.  
 
2.4 Statistical analyses 
 First, differences in medians and proportions were assessed by, respectively, the Kruskal-
Wallis and the chi-square tests. Second, estimated annual percentage changes (EAPC) tested 
temporal trends of MetS and individual MetS components. Third, overall and specific complication 
rates were tested in separate multivariable logistic regression models. All multivariable models 
relied on generalized estimating equations to further adjust for clustering 
26
. Subsequently, data 
distribution was adjusted according to the provided NIS population weights to render estimates 
more accurate nationally 
26
. Multivariable models were fully adjusted for the concomitant presence 
of all four MetS components. Moreover, we expanded the extent of previous analyses, not only by 
combining all possible MetS components among risk factors, but also by testing for dose-response 
from the concomitant effect of multiple MetS components. 
All statistical tests were two-sided with a level of significance set at p<0.05. All analyses were 
performed using the R software environment for statistical computing and graphics (version 3.4.1; 
http://www.r-project. org/).  
         
3. Results 
3.1 Descriptive analyses and trends over time  
 Of 25,875 patients: 1) 59.3% had high blood pressure, 2) 14.7% had BMI 30, 3) 21.7% had 
altered fasting glucose, 4) 20.2% had high triglycerides and 5) <0.01% had low HDL cholesterol 
(Supplementary Figure 1). Respectively, one vs. two vs. three vs. four MetS components were 
recorded in 34.9% vs. 22.9% vs. 8.9% vs. 2.2% patients. Of all patients, 11.1% exhibited  3 
components and qualified for MetS diagnosis (Table 1).  
Time trends revealed an increase in the rates of patients with  3 MetS components (MetS 
definition; EAPC:+12.0%;p<0.001; Supplementary Figure 2a). Similarly, the rates of high blood 
pressure (EAPC:+1.4%;p<0.001; Supplementary Figure 2b), BMI 30 (EAPC:+10.5%;p<0.001; 
Supplementary Figure 2c), altered fasting glucose (EAPC:+2.8%;p<0.002; Supplementary Figure 
2d) and high triglycerides (EAPC:+10.7%;p<0.001; Supplementary Figure 2e) increased over time. 
 
3.2 Crude rates of overall and specific complications according to type of MetS components 
 Patients with high blood pressure exhibited higher rates of overall complications (36.0 vs. 
26.8%;p<0.001). Specifically, patients with high blood pressure exhibited higher rates of 
transfusions, as well as a higher rates of cardiac, miscellaneous medical, vascular, respiratory and 
gastrointestinal complications (Supplementary table 2). 
Patients with BMI 30 exhibited higher rates of overall complications (37.7 vs. 31.3%;p<0.001). 
Specifically, patients with BMI 30 exhibited higher rates of transfusions, as well as higher rates of 
cardiac, miscellaneous medical and respiratory complications. 
Patients with altered fasting glucose exhibited higher rates of overall complications (38.2 vs. 
30.6%;p<0.001). Specifically, patients with altered fasting glucose exhibited higher rates of 
transfusions, as well as higher rates of cardiac, miscellaneous medical, respiratory and 
gastrointestinal complications. 
         
Patients with high triglycerides exhibited higher rates of overall complications (38.2 vs. 30.8%; 
p<0.001). Specifically, patients with high triglycerides exhibited higher rates of transfusions, as 
well as higher rates of cardiac, miscellaneous medical, vascular, respiratory and gastrointestinal 
complications. 
 
3.3 Multivariable analyses according to type of MetS components 
In multivariable logistic regression models predicting overall complications (Table 2), high 
blood pressure (Odds ratio [OR]:1.19;p<0.001), BMI 30 (OR:1.40;p<0.001), altered fasting 
glucose (OR:1.14;p<0.001) and high triglycerides (OR:1.14;p<0.001) achieved independent 
predictor status. Specifically, all four examined MetS components achieved independent predictor 
status in analyses addressing cardiac and miscellaneous medical complications, as well as 
transfusions. In analyses addressing vascular complications, respectively only BMI 30 and high 
triglycerides achieved independent predictor status. In analyses addressing respiratory, infectious 
and wound complications only BMI 30 achieved independent predictor status. Conversely, in 
analyses focusing on intraoperative, gastrointestinal, genitourinary and miscellaneous surgical 
complications, none of the four examined MetS components achieved independent predictor status. 
Subgroup analyses according to PN surgical approach, namely open vs. laparoscopic/robotic 
patients, are reported in Supplementary Table 4. 
 
3.4 Crude rates of overall and specific complications according to number of MetS components 
 Overall complication rates were, respectively, 25.4% vs. 32.4% vs. 36.8% vs. 40.7% vs. 
44.8% in patients with zero vs. one vs. two vs. three vs. four MetS components (Figure 1a). 
Specifically, significant increasing rates of cardiac (Figure 1b), miscellaneous medical (Figure 1d), 
vascular (Figure 1e), respiratory complications (Figure 1f), as well as transfusions (Figure 1b) were 
observed in patients with, respectively, zero vs. one vs. two vs. three vs. four MetS components. 
Conversely, no significant trends were observed between the number of MetS components and the 
         
rates of intraoperative, gastrointestinal, genitourinary, infectious, wound and miscellaneous surgical 
complications (Supplementary table 3). 
 
3.5 Multivariable analyses according to number of MetS components: dose-response effect 
 In multivariable logistic regression models, the ORs indicating the association between the 
number of MetS components and overall complication rates, demonstrated a gradual increase in the 
strength of the association when one (OR:1.23;p<0.001), two (OR:1.44;p<0.001), three (OR:1.77; 
p<0.001) or four (OR:2.13;p<0.001) MetS components were recorded in each individual patient, 
respectively (Table 3). In eleven analyses focusing on specific complications rates, five revealed 
presence of a dose-response effect. Specifically, a dose-response effect was observed in 
multivariable logistic regression models addressing cardiac, miscellaneous medical, vascular and 
respiratory complications, as well as transfusions. Conversely, in the six remaining models focusing 
on intraoperative, gastrointestinal, genitourinary, infectious, wound and miscellaneous surgical 
complications, no dose-response effect was identified. 
Subgroup analyses according to PN surgical approach, namely open vs. laparoscopic/robotic 
patients, are reported in Supplementary Table 5. 
  
         
4. Discussion 
 The association between MetS and early adverse perioperative outcomes after PN has been 
poorly investigated 
5–9
. However, obesity 
10,12–15,17
, hypertension 
20,21
 and diabetes 
21,23–25
 have been 
previously related to higher complication rates after PN. These analyses did not account for the 
simultaneous effect of other MetS components. In consequence, they could not validate an 
independent predictor status for each component in isolation, when the effect of other MetS 
components is accounted for. Finally, these analyses could not test the possibility of a dose-
response relationship when >1 MetS component is at play. Based on these limitations, we examined 
the relationship between four established MetS components (high blood pressure, BMI 30, altered 
fasting glucose and high triglycerides) and perioperative complications after PN. We hypothesized 
that presence of one and, to an even greater extent of multiple MetS components, may predispose to 
higher complication rates after PN. Our results showed several important findings. 
     First, MetS patients account for, approximately, 11% of contemporary PN series. Moreover, 
the rates of MetS diagnosis based on presence of at least three MetS components (EAPC:+12.0%) 
and the rates of MetS single components increased over time. Our results corroborate previous 
National Health and Nutrition Examination Survey (NHANES) data 
2
 and validate the notion that 
the increasing rates of MetS is gaining in momentum.  
 Second, each of the four examined MetS components (high blood pressure, BMI 30, 
altered fasting glucose and high triglycerides) achieved independent predictor status as unique risk 
variables in four out of twelve multivariable models predicting overall, cardiac and miscellaneous 
medical complications, as well as transfusions, even after full adjustment for patient and hospital 
characteristics, as well as after full adjustment for other MetS components. Moreover, BMI 30 was 
also associated with higher rates of vascular, respiratory, infectious and wound complications. 
Additionally, high triglycerides were also associated with higher rates of vascular complications. 
Finally, no meaningful differences were observed in subgroup analyses according to open vs. 
laparoscopic/robotic PN approach. Our findings build upon previous reports, where individual MetS 
         
components have been examined, but were never tested after full adjustment for the effect of the 
remaining MetS components 
10,13–15,21,23–25
. To the best of our knowledge, we are the first to 
demonstrate the individual ability of each MetS component, even when all others components are 
fully accounted for. Our findings indicate that in the context of PN early perioperative outcomes, 
presence of one or several MetS components may identify individuals at higher risk of perioperative 
complications. Our database allowed us to examine the effect of each MetS component when it was 
coded in a dichotomized fashion (normal vs. abnormal). Unfortunately, we have no access to 
continuously coded values for the five MetS components. It is possible that additional predictive 
information may be derived from an analysis that relies on continuously coded MetS components. 
Third, unlike in previous analyses, we tested for dose-response effect and confirmed that an 
increasing number of MetS components is directly proportional to the magnitude of six out of 
twelve examined endpoints: overall, cardiac, miscellaneous medical, vascular and respiratory 
complications, as well as transfusions. The magnitude of the dose-response effect was strongest in 
analyses addressing overall and cardiac complications, it was intermediate in analyses addressing 
transfusions and miscellaneous medical complications and it was weakest in analyses addressing 
vascular and respiratory complications. Despite the variable effect on the magnitude of adverse 
perioperative outcomes, all dose-response relationships demonstrated independent predictor status 
for each unit increase in the number of present MetS components. These observations are 
particularly important, since they illustrate that even the presence of one MetS component is 
associated with higher risk of perioperative complications. Therefore, patients who do not yet meet 
the diagnosis of MetS, based on presence of one or only two MetS components, should still be 
considered at an elevated risk of early adverse events after PN and represent candidates for 
preventative measures, if applicable. For example, pre-operative nutrition therapies, lifestyle 
changes and statins use could represent preventive measures that may modify peri-anaesthetic and 
surgical risks in MetS patients 
29
. Last but not least, findings of this work failed to show statistically 
significant associations between surgical approach (namely: open vs. laparoscopic/robotic PN) and 
         
perioperative complications among patients with MetS. In consequence, MetS patients should be 
properly informed about the risk of higher perioperative complications after PN, regardless of 
surgical approach proposed. 
Fourth, it is important to emphasize differences in MetS rates according to its definition 
within retrospective analyses. In all such initiatives, MetS presence is established based on its five 
components, which may be identified using specific diagnostic codes. Even though we relied on a 
standardized definition 
1,27,28
 to identify each of the five MetS components, we recorded a very low 
rate of low HDL cholesterol levels. Different prevalence rates of low HDL cholesterol and of other 
MetS components have been reported by several investigators 
2,7,9
. Moreover, MetS patients could 
be more frequently addressed to other nonsurgical option, that are usually reserved to surgical unfit 
patients. Therefore, MetS should ideally be examined within a prospectively gathered database 
designed with this intent. Until such analysis has been completed, it will be difficult to validly 
explain discrepancies observed in various retrospective databases. Nonetheless, the overwhelming 
agreement between all analyses about the importance of MetS components with respect to their 
associations with perioperative complications after PN, convincingly implicates either individual 
MetS components or their combined effect in the association with these adverse endpoints. Our 
findings are also supported by previous findings from other surgical areas. Specifically, MetS was 
associated with higher rates of perioperative complications in non-oncological patients treated with 
cardiovascular, neurosurgical or orthopedic surgery 
28,29
. Moreover, higher rates of perioperative 
adverse events had been observed in surgically treated MetS patients with breast, colorectal or liver 
cancer
27,29
.   
Taken together, to the best of our knowledge, we provided the first large scale attempt to test 
the ability of MetS, defined according to the International Diabetes Federation and the American 
Heart Association/National Heart, Lung, and Blood Institute 
1
, to predict worse overall and specific 
perioperative complications, in PN treated patients. Our analyses showed that MetS patients 
accounted for almost 11% of the PN population and that the proportion of MetS patients increased 
         
over time. Moreover, MetS components achieved independent predictor status in multivariable 
models addressing overall and several specific perioperative complications, even after adjustment 
for patient and hospital characteristics, as well as adjustment for other MetS components. Last but 
not least, a dose-response effect was observed when MetS components were combined into five risk 
strata. In consequence, MetS may qualify as an important risk factor for identification of patients at 
risk for higher rates of perioperative complications after PN. 
Despite its novelty, our study has limitations. First, the data are retrospective. In 
consequence, our analysis represents a weak substitute for prospective randomized comparisons 
between MetS vs. non-MetS patients treated with PN. Second, within the NIS database 
26
, 
complications are limited to in-hospital events. In consequence, delayed complications, as well as 
the readmission rate, could not be examined. Third, information on performance status, ASA score, 
lookback period of CCI assessment, as well as laboratory values, are not available within the NIS 
database. Finally, since the NIS database does not provide tumor characteristics, such as stage and 
grade, we were unable to adjust our analyses for these variables.  
  
         
5. Conclusion 
MetS and its components consistently and strongly predict perioperative complications after 
PN. Moreover, the strength of the effect was directly proportional to the number of MetS 
components exhibited by each individual patient, even if formal MetS diagnosis of  3 components 
has not been met.  
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Figure legends 
 
Figure 1. Barplots depicting crude rates of overall and specific complications, according to number of 
metabolic syndrome components, in 25,875 partial nephrectomy patients (unweighted population) 
identified within National (Nationwide) Inpatient Sample (NIS) database from 2000 to 2015.  
             A) Overall complications; B) Cardiac complications; C) Transfusions; D) Miscellaneous medical 
complications; E) Vascular complications; F) Respiratory complications 
 
 
         
Table 1. Descriptive characteristics of 25,875 partial nephrectomy patients (unweighted population) identified within National (Nationwide) Inpatient 
Sample (NIS) database from 2000 to 2015 and stratified according to presence or absence of metabolic syndrome.  IQR: interquartile range; CCI: 
Charlson Comorbidity Index 
 
  Metabolic syndrome: Yes 
(n=2,878; 11.1%) 
Metabolic syndrome: No 
(n=22,997; 88.9%) 
p-value 
Age (years) Median (IQR) 63 (56-70) 60 (50-68) <0.001 
Gender, n (%) Male 1,701 (59.1) 14,299 (62.2) 0.001 
 Female 1,177 (40.9) 8,698 (37.8)  
Ethnicity, n (%)  Caucasian 1,878 (65.3) 15,069 (65.5) <0.001 
 African-American 322 (11.2) 2,016 (8.8)  
 Other 678 (23.6) 5,912 (25.7)  
CCI, n (%)  0-1 1,975 (68.6) 20,977 (91.2) <0.001 
  2 903 (31.4) 2,020 (8.8)  
Surgical approach, n (%) Open 1,848 (64.2) 16,005 (69.6) <0.001 
         
 Laparoscopic 138 (4.8) 1,457 (6.3)  
 Robotic 892 (31) 5,535 (24.1)  
Year of diagnosis, n (%) 2000-2007 400 (13.9) 7,756 (33.7) <0.001 
 2008-2015 2,478 (86.1) 15,241 (66.3)  
Lymphadenectomy, n (%) No 2,860 (99.4) 22,812 (99.2) 0.4 
 Yes 18 (0.6) 185 (0.8)  
Insurance status, n (%) Medicare 1,306 (45.4) 8,152 (35.4) <0.001 
 Medicaid 173 (6) 1,346 (5.9)  
 Private 1,271 (44.2) 12,218 (53.1)  
 Other 128 (4.4) 1,281 (5.6)  
Region, n (%) Midwest 802 (27.9) 5,020 (21.8) <0.001 
 Northeast 576 (20) 5,824 (25.3)  
 South 1,018 (35.4) 8514 (37)  
 West 482 (16.7) 3,639 (15.8)  
         
  
 
 
 
 
  
Income, n (%) 1st quantile 728 (25.3) 5,208 (22.6) <0.001 
 2nd quantile 726 (25.2) 5,197 (22.6)  
 3rd quantile 750 (26.1) 5,779 (25.1)  
 4th quantile 674 (23.4) 6,813 (29.6)  
Annual hospital volume, n (%) Low 810 (28.1) 7,800 (33.9) <0.001 
 Medium 966 (33.6) 7,198 (31.3)  
 High 1,102 (38.3) 7,999 (34.8)  
Teaching status, n (%) Teaching 2,111 (73.3) 16,872 (73.4) 0.9 
 Non teaching 767 (26.7) 6,125 (26.6)  
Hospital bedsize, n (%) Small 307 (10.7) 2,360 (10.3) 0.4 
 Medium 575 (20) 4,422 (19.2)  
 Large 1,996 (69.4) 16,215 (70.5)  
         
Table 2. Separate multivariable logistic regression models predicting overall and specific complications in patients treated with partial nephrectomy 
for renal cell carcinoma within the National Inpatient Sample database (2000-2015), according to presence or absence of metabolic syndrome 
components. All models were weighted and adjusted for clustering, as well as age, year of surgery, gender, ethnicity, insurance status, teaching 
status, hospital volume, region, hospital bed-size, income, lymph node dissection, surgical approach, as well as for all four examined metabolic 
syndrome components. OR=odds ratio, CI=confidence interval 
 
 High blood pressure  
(Yes vs. No) 
BMI 30  
(Yes vs. No) 
Altered fasting glucose  
(Yes vs. No) 
High triglycerides  
(Yes vs. No) 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
OVERALL 1.19 (1.12-1.27) <0.001 1.40 (1.29-1.51) <0.001 1.14 (1.07-1.21) <0.001 1.14 (1.06-1.22) <0.001 
CARDIAC 1.14 (1.00-1.33) 0.03 1.68 (1.43-1.98) <0.001 1.73 (1.51-1.97) <0.001 1.20 (1.04-1.38) 0.01 
TRANSFUSIONS 1.22 (1.10-1.36) <0.001 1.34 (1.10-1.40) <0.001 1.35 (1.22-1.50) <0.001 1.11 (1.02-1.23) 0.03 
MISCELLANEOUS 
MEDICAL 
1.24 (1.14-1.35) <0.001 1.23 (1.11-1.35) <0.001 1.18 (1.09-1.29) <0.001 1.13 (1.03-1.23) 0.005 
VASCULAR 1.13 (0.85-1.49) 0.3 1.45 (1.05-1.99) 0.02 0.83 (0.63-1.10) 0.2 1.74 (1.33-2.28) <0.001 
RESPIRATORY 1.07 (0.96-1.19) 0.1 1.34 (1.18-1.52) <0.001 1.01 (0.91-1.13) 0.7 1.06 (0.95-1.19) 0.2 
INTRAOPERATIVE 1.12 (0.92-1.36) 0.2 1.13 (0.87-1.46) 0.3 0.85 (0.68-1.07) 0.1 0.79 (0.61-1.02) 0.07 
GASTROINTESTINAL 0.97 (0.87-1.07) 0.5 0.96 (0.84-1.09) 0.5 1.03 (0.92-1.15) 0.5 1.08 (0.97-1.21) 0.1 
GENITOURINARY 0.95 (0.80-1.12) 0.5 1.15 (0.92-1.43) 0.2 0.96 (0.79-1.15) 0.6 0.91 (0.76-1.11) 0.3 
INFECTIOUS 0.65 (0.49-1.01) 0.7 1.66 (1.17-2.36) 0.004 0.96 (0.72-1.29) 0.8 0.91 (0.63-1.41) 0.9 
WOUND 0.93 (0.66-1.19) 0.4 1.58 (1.04-2.42) 0.03 0.70 (0.47-1.04) 0.08 1.67 (0.42-1.05) 0.08 
         
MISCELLANEOUS 
SURGICAL 
0.96 (0.83-1.10) 0.5 1.13 (0.94-1.35) 0.1 0.85 (0.73-1.01) 0.06 0.94 (0.80-1.10) 0.4 
 
 
Table 3. Separate multivariable logistic regression models predicting overall and specific complications in patients treated with partial nephrectomy 
for renal cell carcinoma within the National Inpatient Sample database (2000-2015), according to number of metabolic syndrome components. All 
models were weighted and adjusted for clustering, as well as age, year of surgery, gender, ethnicity, insurance status, teaching status, hospital 
volume, region, hospital bed-size, income, lymph node dissection, surgical approach. OR=odds ratio, CI=confidence interval 
 
 One vs. Zero components Two vs. Zero components Three vs. Zero components Four vs. Zero components 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
OVERALL 1.23 (1.15-1.32) <0.001 1.44 (1.34-1.56) <0.001 1.77 (1.60-1.97) <0.001 2.13 (1.78-2.54) <0.001 
CARDIAC 1.27 (1.05-1.53) 0.01 1.80 (1.48-2.19) <0.001 2.86 (2.27-3.59) <0.001 3.73 (2.68-5.19) <0.001 
TRANSFUSIONS 1.27 (1.12-1.43) <0.001 1.41 (1.23-1.61) <0.001 1.92 (1.63-2.26) <0.001 2.34 (1.80-3.05) <0.001 
MISCELLANEOUS 
MEDICAL 
1.23 (1.11-1.35) <0.001 1.42 (1.28-1.57) <0.001 1.64 (1.44-1.88) <0.001 2.42 (1.97-2.98) <0.001 
VASCULAR 1.22 (1.00-1.72) 0.04 1.55 (1.07-2.24) 0.01 1.90 (1.24-2.91) 0.003 2.13 (1.11-4.06) 0.02 
RESPIRATORY 1.18 (1.04-1.35) 0.001 1.18 (1.03-1.36) 0.01 1.41 (1.19-1.67) <0.001 1.56 (1.16-2.10) 0.003 
INTRAOPERATIVE 1.10 (0.89-1.37) 0.3 1.05 (0.82-1.35) 0.6 0.96 (0.66-1.39) 0.8 0.53 (0.23-1.25) 0.1 
         
GASTROINTESTINAL 1.05 (0.93-1.17) 0.3 1.00 (0.87-1.14) 0.9 1.03 (0.87-1.22) 0.7 1.20 (0.90-1.59) 0.1 
GENITOURINARY 0.93 (0.77-1.12) 0.4 0.88 (0.71-1.08) 0.2 0.78 (0.57-1.06) 0.1 0.89 (0.52-1.53) 0.6 
INFECTIOUS 0.71 (0.57-1.07) 0.1 0.66 (0.42-1.11) 0.2 0.92 (0.76-1.18) 0.4 1.02 (0.46-2.25) 0.9 
WOUND 0.69 (0.48-1.00) 0.05 0.64 (0.35-1.16) 0.2 0.62 (0.34-1.14) 0.1 0.79 (0.27-2.27) 0.6 
MISCELLANEOUS 
SURGICAL 
0.95 (0.81-1.11) 0.5 0.93 (0.78-1.11) 0.4 0.91 (0.72-1.17) 0.4 0.69 (0.42-1.14) 0.1 
 
 
         
